Skip to main content
Publications
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Ferrer P, Sabate M, Ballarin E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibanez L. Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010. Springerplus. 2015 Oct 15;4:612. doi: 10.1186/s40064
Serrano NC, Casas JP, Díaz LA, Páez C, Mesa CM, Cifuentes R, Monterrosa A, Bautista A, Hawe E, Hingorani AD, Vallance P, López-Jaramillo P. Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. J Clin Hypertens (Greenwich). 2004;44(5):702-7.
Miller GJ, Li P, Jones A, Humphries SE, Luong L, Payne JR, Montgomery HE, Hawe E, Dhamrait SS, Wootton PT, Toor IS. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. J Clin Hypertens (Greenwich). 2003 Oct;42(4):500-6.